Drug Profile

CDI 988

Alternative Names: CDI-988

Latest Information Update: 17 Sep 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Cocrystal Pharma Inc
Class Antivirals; Small molecules
Mechanism of Action 3C viral protease inhibitors; Coronavirus 3C-like proteinase inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Phase I COVID 2019 infections; Norovirus infections

Most Recent Events

12 Sep 2025 US FDA approves IND application for CDI 988 in Norovirus infection, prior to September 2025
08 Sep 2025 Cocrystal Pharma received a study may proceed letter from the USFDA to conduct a phase Ib challenge study for CDI 988 in norovirus infections
08 Sep 2025 Pharmacodynamics data from a preclinical study in Norovirus infection released by Cocrystal Pharma

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com